Displaying items by tag: Division of Hematology and Oncology

This summer, MS2s Jessica Wu and Geoffrey Bostany are working on forward-thinking projects in the lab of Smita Bhatia, M.D., MPH, director of the Institute for Cancer Outcomes and Gay and Bew White Endowed Chair in Pediatric Oncology.

On March 25, 2020, the School of Medicine and the Hugh Kaul Precision Medicine Institute issued a request for applications that would change the course of research at UAB. A year later, the 14 selected projects have led to new discoveries, subsequent funding, high impact publications, and much more.

UAB Medicine recently established a colorectal oncology clinic to provide a hassle-free experience for diagnosis and treatment.
Clinical trials from the final Department of Medicine divisions recently went live in OnCore, marking the successful completion of another major phase of the implementation plan. OnCore is replacing the older, and no longer supported, SiteMinder system.
The UAB Comprehensive Cancer Center has received a prominent national Innovator Award from the Association of Community Cancer Centers (ACCC) for its Patient Care Connect Program. The award is given only to ACCC members that are forward-thinking in creating replicable solutions to improve access, quality and value of patient care.
A UAB researcher has received a 2017 Susan G. Komen grant to investigate combination drug therapies for HER2-positive breast cancer.
Recent findings from an innovative nationwide trial indicate that the drug pembrolizumab, when used in combination with standard therapy, may provide positive results for patients with locally advanced breast cancer.
Michael Birrer, a leading medical oncologist at Harvard University, will take the reins as the new director of the UAB Comprehensive Cancer Center, succeeding the retiring Edward Partridge.
The first target for the UAB spinoff Incysus Ltd. will be glioblastoma. Incysus has just received a European patent for its innovative approach to fighting cancer.
Page 2 of 5